TY - JOUR
T1 - Desensitization to rituximab in a multidisciplinary setting
AU - Amorós-Reboredo, Patrícia
AU - Sánchez-López, Jaime
AU - Bastida-Fernández, Carla
AU - do Pazo-Oubiña, Fernando
AU - Borràs-Maixenchs, Núria
AU - Giné, Eva
AU - Valero, Antonio
AU - Creus-Baró, Natàlia
N1 - Publisher Copyright:
© 2015, Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie.
PY - 2015/10/1
Y1 - 2015/10/1
N2 - Background The need to offer first-line therapy to the increasing number of patients who have suffered an hypersensitivity reaction has stimulated the use of rapid desensitization protocols. Objective To present our experience working as a multidisciplinary team using a rituximab rapid desensitization scheme. Method Patient demographics, allergic reaction, skin tests to rituximab, number of desensitizations, reactions during the desensitization protocol and actions taken, number of administered and completed cycles, were retrospectively collected in patients who received at least one desensitization to rituximab. Main outcomes Number of desensitizations successfully managed. Results Between 2012 and June 2013 five patients received a total of 19 desensitizations to rituximab using a 12 step rapid desensitization protocol. All patients received the scheduled chemotherapeutic cycles as inpatients, with no delay in administration dates. Three patients presented a hypersensitivity reaction during the first desensitization and in one patient the event occurred again during the second treatment cycle. All reactions occurred in the last step, when the infusion rate reached the maximum speed. Conclusion The developed protocol for rapid desensitization was successful in five patients receiving rituximab. Patients could receive the full intended dose.
AB - Background The need to offer first-line therapy to the increasing number of patients who have suffered an hypersensitivity reaction has stimulated the use of rapid desensitization protocols. Objective To present our experience working as a multidisciplinary team using a rituximab rapid desensitization scheme. Method Patient demographics, allergic reaction, skin tests to rituximab, number of desensitizations, reactions during the desensitization protocol and actions taken, number of administered and completed cycles, were retrospectively collected in patients who received at least one desensitization to rituximab. Main outcomes Number of desensitizations successfully managed. Results Between 2012 and June 2013 five patients received a total of 19 desensitizations to rituximab using a 12 step rapid desensitization protocol. All patients received the scheduled chemotherapeutic cycles as inpatients, with no delay in administration dates. Three patients presented a hypersensitivity reaction during the first desensitization and in one patient the event occurred again during the second treatment cycle. All reactions occurred in the last step, when the infusion rate reached the maximum speed. Conclusion The developed protocol for rapid desensitization was successful in five patients receiving rituximab. Patients could receive the full intended dose.
KW - Desensitization
KW - Drug hypersensitivity
KW - Rituximab
KW - Spain
UR - http://www.scopus.com/inward/record.url?scp=84943197940&partnerID=8YFLogxK
UR - https://www.webofscience.com/wos/woscc/full-record/WOS:000362415800014?SID=EUW1ED0E70ECgAmg8vb3ZwbcOy7jo
U2 - 10.1007/s11096-015-0136-x
DO - 10.1007/s11096-015-0136-x
M3 - Article
C2 - 25999014
AN - SCOPUS:84943197940
SN - 2210-7703
VL - 37
SP - 744
EP - 748
JO - International Journal of Clinical Pharmacy
JF - International Journal of Clinical Pharmacy
IS - 5
ER -